Lentiviral Gene Therapy with Reduced-Intensity Conditioning for Sickle Cell Disease: A Phase 1/2 Trial
Lentiviral Gene Therapy with Reduced-Intensity Conditioning for Sickle Cell Disease: A Phase 1/2 Trial - integration site data (SCGT samples)